1. Most Discussed
  2. Gainers & Losers

vostech vos thoughts?

  1. LETTER FROM THE CHAIRMAN

    On behalf of the current and proposed board of Directors of your
    company, I am delighted to offer you this opportunity to invest in
    VosTech Limited (VosTech or Company) and participate in the future
    potential of the Company's new biotechnology acquisitions.

    Subject to approval by the Company's shareholders at the General
    Meeting being convened on 12 August 2002, VosTech will make offers to
    acquire 100% of the capital of Brightsun, an animal biotechnology
    company.

    Brightsun is focussing on the research, development and
    commercialisation of biological solutions for both companion and
    production animals. The aim of these biological solutions is to
    improve the health and welfare of animals, increase productivity at
    an economical cost, and reduce the use of chemicals and drugs,
    particularly antibiotics, in production animals.

    Increasing awareness of the influence of chemical and antibiotic
    residues on human health, animal health and the human food chain, and
    the emergence of drug and chemical resistance, dictates that more
    acceptable alternative solutions to animal healthcare problems are
    developed to reduce the widespread and often detrimental use of these
    chemicals and drugs.

    The use of certain antibiotics in food producing animals is already
    subject to regulation, with some additives prohibited in certain
    countries reflecting the acknowledgment of the role of residues from
    meat or poultry meat in the development of antibiotic resistance in
    bacterial diseases of humans, or the so-called "superbugs".

    The initial projects that Brightsun has identified are the result of
    years of dedicated research by the research teams at both the
    Livestock Industries division at the Commonwealth Scientific and
    Industrial Research Organisation (CSIRO) and the Division of
    Veterinary and Biomedical Sciences at Murdoch University.

    The initial production animal solutions are targeting the pig and
    poultry health products markets world-wide which are estimated to be
    in excess of US$8 billion per annum. These solutions comprise a
    vaccine delivery system, specific vaccines targeting commercially
    important diseases and biotherapeutics and productivity enhancers
    that aim to replace the current antibiotic usage.

    The initial companion animal solution under development is for an
    efficient and biological flea control vaccine. The current companion
    animal flea control product global market is estimated at US$2
    billion per annum, the dominant products being either chemically
    based or having low rates of efficacy.

    The production animal solutions are at an advanced stage of
    development with a number of key patents granted in the USA and other
    developed countries, with others under application. Milestone based
    commercial understandings with major veterinary pharmaceutical
    companies have been reached, although not executed, for the
    evaluation and development of certain products in specific geographic
    areas.

    The acquisition of Brightsun provides access to these well
    established biotechnology projects. These projects aim to improve
    disease or parasite control in animals and poultry, reduce the use of
    harmful chemicals and drugs, and reduce the level of chemical and
    antibiotic residue entering the human food chain. The potential and
    existing markets for these products is large, with the opportunity
    for these new products to replace existing products and create new
    markets. The products are all biologically based.

    The capital raised pursuant to the Offers contained within this
    Prospectus will be utilised in furthering the Company's development
    of its existing technology and the biotechnology investments to be
    acquired as a result of the Brightsun transactions.

    I recommend this investment opportunity to you.

    D Steinepreis
    CHAIRMAN

DISCLAIMER:
Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.

Top